TMEM101

Across TCGA pan-cancer cohorts, TMEM101 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TMEM101 data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher TMEM101 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TMEM101 expression acts as an unfavorable survival marker.

STAD, BRCA, and LIHC are the cancer types where TMEM101 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.022	0.731	<.001	24	view →
BRCA	OS	Median	All	0.621	0.963	.010	12	view →
LIHC	DFS	Median	All	0.107	0.545	<.001	12	view →
LUSC	OS	Median	All	0.196	0.762	.008	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TMEM101–STAD (OS)

Open the STAD breakdown →